| Document |
Document Title |
|
WO/2022/088853A1 |
The present invention relates to an organometallic compound and an application thereof. The organometallic compound has a structure represented by formula (1). The compound provided by the present invention has the advantages of high opt...
|
|
WO/2022/090409A1 |
The invention relates to novel deuterated compounds of Formula (I) to a process for their preparation and to their use as medicament, in particular as antiviral medicament.
|
|
WO/2022/094609A1 |
Described herein are compounds that are useful for delivering therapeutic, diagnostic, and imaging agents. Also described herein are pharmaceutical compositions containing such compounds and methods of using the compounds and composition...
|
|
WO/2022/071449A1 |
This deuterated aromatic compound production method for producing a deuterated aromatic compound comprises a step for deuterating an aromatic compound in a deuterium-containing solvent, wherein: the aromatic compound has a structure in w...
|
|
WO/2022/063016A1 |
The present invention relates to a deuterated dihydrodibenzothiepine compound, a tautomer, stereoisomer, prodrug, pharmaceutically acceptable salt, hydrate, or solvate thereof, a pharmaceutical composition containing the compound, and a ...
|
|
WO/2022/058192A1 |
Phosphatidylalkanol homologues having isotopically labelled moieties, methods for preparation of isotopically labelled phosphatidylalkanol homologues and uses of isotopically labelled phosphatidylalkanol homologues.
|
|
WO/2022/053459A1 |
The current invention provides a method for performing chemical reactions of radioactive compounds, and a device, system and method for improved heating for chemical reactions.
|
|
WO/2022/045837A1 |
The present specification relates to a method for preparing a deuterated aromatic compound and a deuterated composition.
|
|
WO/2022/045825A1 |
The present specification relates to a method for preparing a deuterated aromatic compound and a deuterated composition.
|
|
WO/2022/045838A1 |
The present specification relates to a method for preparing a deuterated aromatic compound, and a deuterated reactive composition.
|
|
WO/2022/043993A1 |
The present invention provides PCNHCP pincer metal complexes, which are useful as catalysts in various chemical reactions such as hydrogen isotope exchange (HIE) in C(sp3)-H and/or C(sp2)-H bond of an organic compound, e.g., a pharmaceut...
|
|
WO/2022/038572A1 |
The present disclosure relates to [18F]-labeled imidazopyridine derivatives or salts thereof as positron emission tomography (PET) radiotracers suitable for imaging the stress-signaling non-receptor tyrosine kinase c-abl, and their use i...
|
|
WO/2022/034544A1 |
This invention relates to a hydroxamate metalloprotease inhibitor compound for use in a method of diagnosing or treating cancer, inflammatory diseases or Alzheimer's disease. The compound comprises a zinc-chelating N-hydroxamate moiety r...
|
|
WO/2022/034143A1 |
The present invention relates to an adduct comprising at least one transition metal and an adduct between a sp2 carbon allotrope and a pyrrole compound. In particular, the invention relates to an adduct comprising at least one transition...
|
|
WO/2022/028557A1 |
A 18F-labeled biphenyl compound, an intermediate thereof, a preparation method therefor, a pharmaceutical composition thereof, and application thereof. The biphenyl compound has a significant suppression effect on PD-1 and/or PD-L1, can ...
|
|
WO/2022/031946A1 |
Provided herein are compounds of Formula I and imaging agents useful for detecting a disease or condition associated with protein aggregation, compositions thereof, and methods of their use.
|
|
WO/2022/026533A1 |
Embodiments of the present disclosure provide compositions and methods for performing positron emission tomography (PET) and, more particularly, to compositions and methods for the development and use of 18F-based PET tracers for use in ...
|
|
WO/2022/019336A1 |
The purpose of the present invention is to provide: a novel deuterated labeling compound; and a production method therefor. The present invention provides: a deuterated labeling compound in which at least position β of a fatty acid is d...
|
|
WO/2022/016690A1 |
Provided are luciferase substrates, a preparation method therefor and an application thereof. The luciferase substrates have the advantages of good selectivity, high sensitivity, a low detection line and good biocompatibility, and so on;...
|
|
WO/2022/018264A1 |
Provided is a ligand compound, comprising (a) a targeting group, (b) one or more chelating groups, optionally containing a chelated radioactive or non-radioactive cation, and (c) a group carrying an Si-OH functional moiety. The ligand co...
|
|
WO/2022/008006A1 |
The invention relates to compounds of the general formula (I) wherein X1 is a CD2 group or a CT2 group; X2 is oxygen or a group (CZ1Z2)n, with Z1 and Z2 independently of each other being hydrogen, deuterium or tritium and n being an inte...
|
|
WO/2022/003426A1 |
Provided herein are crystalline forms of deuterium-enriched (R)-pioglitazone and compositions thereof. Also provided herein are methods of using the crystalline forms of deuterium-enriched (R)-pioglitazone and compositions thereof.
|
|
WO/2021/259869A1 |
The present invention relates to cell radiolabelling agents. The invention provides a method of preparing oxine-containing cell radiolabelling agents, a kit for the preparation of oxine-containing cell radiolabelling agents and a formula...
|
|
WO/2021/250240A1 |
The invention relates to a diaza-18-crown-6 derivative having formula (I): wherein: B is a moiety for a covalent bonding reaction; the two A are identical to each other and are a group of formula (II): where: n = 0 to 4; X1, X2, X3, X4 a...
|
|
WO/2021/226076A1 |
This invention provides a composition comprising the compound having the structure: ethyl 2-[19F]F-4-nitrobenzoate, and at least one acceptable carrier. This invention also provides a method of detecting the presence of or location of ba...
|
|
WO/2021/225147A1 |
For the purpose of producing astatine-211 free from chloride ions with high yield, an astatine-211 production method is provided, the method being characterized by comprising: (1) a step for irradiating bismuth with an α ray to produce ...
|
|
WO/2021/218588A1 |
The present application belongs to the field of organic light-emitting materials, and specifically relates to a nitrogen-containing compound, an electronic component using same and an electronic device. The nitrogen-containing compound h...
|
|
WO/2021/219719A1 |
The present disclosure relates to methods for radiolabelling PSMA binding ligands with a radioactive isotope, preferably 68Ga, 67Ga or 64Cu, and their kits.
|
|
WO/2021/219720A1 |
The present invention relates to methods for labeling a PSMA binding ligand with a radioactive isotope, preferably 68Ga, 67Ga or 64Cu, said method comprising the steps of: i. providing a single vial comprising, in dried form, said PSMA b...
|
|
WO/2021/222153A1 |
There are disclosed compounds of the following formula I or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFN?, by ac...
|
|
WO/2021/195403A1 |
The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseas...
|
|
WO/2021/188188A1 |
Disclosed herein are methods for imaging a tissue in a subject that involves administering to the subject a composition comprising deuterium-labeled glycolytic or fatty acid substrate and imaging the subject with deuterium magnetic reson...
|
|
WO/2021/167008A1 |
This method for producing an aromatic astatine compound comprises reacting aromatic iodonium ylide with astatine to produce an aromatic astatine compound.
|
|
WO/2021/150223A1 |
The present disclosure relates to systems and methods for producing tailored solutions or medicaments containing radioactive isotopes (e.g., alpha particle emitting radioactive isotopes). The solutions may be produced by appropriate agin...
|
|
WO/2021/146572A1 |
A compound of the Formula I or a pharmaceutically acceptable salt thereof, wherein R1, Ca, Cb, Cd, and n are the same as described in the specification. Disclosed is a method of diagnosing or monitoring a patient suffering from cancer, t...
|
|
WO/2021/142238A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that exhibit activity as mitochondrial uncoupling agents. Said...
|
|
WO/2021/123073A1 |
The present invention provides a cassette for determining optimised solid phase extraction (SPE) purification conditions, wherein said cassette comprises: (i) a flowpath comprising a first end and a second end; and (ii) a plurality of va...
|
|
WO/2021/127265A1 |
Provided herein are certain compounds of formula (I) and imaging agents useful for detecting a condition or disorder associated with protein aggregation, compositions thereof, and methods of their use.
|
|
WO/2021/118887A1 |
The present invention provides a compound of Formula I: wherein R1 is hydrogen, F, or 18F; and R2 is hydrogen, F, or 18F; or a pharmaceutically acceptable salt thereof, provided that when R1 is 18F then R2 is not 18F, useful as a CGRP re...
|
|
WO/2021/096968A1 |
The application is drawn to radiohalogen prosthetic moieties and precursors thereof and to radiolabeled biomolecules comprising such radiohalogen prosthetic moieties. The biomolecules have an affinity for particular types of cells and ma...
|
|
WO/2021/093556A1 |
Disclosed is a method for preparing a compound I. The method comprises a reaction system comprising a compound II, which contains a carbon-oxygen double bond, and further comprising water, deuterated water, or tritiated water, which is p...
|
|
WO/2021/088223A1 |
The present invention belongs to the technical field of isotope labeling chemical synthesis, and disclosed is a method for synthesizing a deuterated compound in an aqueous phase solvent. The method involves, based on the following chemic...
|
|
WO/2021/090850A1 |
The present invention relates to a compound represented by general formula (1) or a salt thereof. In general formula (1), R1, R2, R3 and R4 are each independently a hydrogen atom, an optionally substituted straight-chain or a branched ...
|
|
WO/2021/078814A1 |
The present invention provides a radiopharmaceutical composition comprising the following four components: (i) a radio-labelled compound; (ii) ethanol; (iii) a stabilizer of the radio-labelled compound; and (iv) a cyclodextrin. The prese...
|
|
WO/2021/080409A1 |
Human prostate tumours display intrinsic heterogeneity and changes in phenotype as the disease progresses, which involves various levels of cell-surface receptor expression. The invention relates to a new radiolabelled (Lys3)bombesina-iP...
|
|
WO/2021/048241A1 |
The invention provides new radiolabeled monoacylglycerol lipase (MAGL) inhibitors that are useful for medical imaging, such as positron-emission tomography (PET), single-photon emission computed tomography (SPECT) and/or autoradiography.
|
|
WO/2021/025984A1 |
Disclosed herein are compounds having a structure according to Formula I and optionally Formula IV. Formula I Formula IV. The compounds may be radiolabeled compounds useful for diagnosis and/or imaging fungal infections. In such embodime...
|
|
WO/2021/003314A1 |
Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
|
|
WO/2020/253824A1 |
The present invention belongs to the technical field of radiopharmaceutical chemistry, and provided are 18F-labeled fluoropicolinylglycine as well as a preparation method therefor and an application thereof. The 18F-labeled fluoropicolin...
|
|
WO/2020/255049A1 |
The present invention provides a novel, simple, unique and viable processes for the synthesis of deuterium incorporated eugenols, such as deuterated eugenol (II), regioisomeric deuterated eugenol (III), and deuterated variant of methyl e...
|
